07th week of 2012 patent applcation highlights part 34 |
Patent application number | Title | Published |
20120039915 | GLIOBLASTOMA MULTIFORME-REACTIVE ANTIBODIES AND METHODS OF USE THEREOF - The present disclosure is generally related to antibodies that bind specifically to glioblastoma multiforme (GBM) cells. In particular, the present disclosure provides compositions comprising human single chain or full-length antibodies that bind tumor cells. Additionally the present disclosure provides methods of using the anti-GBM antibodies. | 2012-02-16 |
20120039916 | NOVEL VACCINE ADJUVANTS BASED ON TARGETING ADJUVANTS TO ANTIBODIES DIRECTLY TO ANTIGEN-PRESENTING CELLS - Compositions and methods for enhancing an immune response with an adjuvant composition comprising: an anti-dendritic cell (DC)-specific antibody or fragment thereof conjugated to at least a portion of a TLR agonist; and a pharmaceutically acceptable carrier are disclosed herein. The conjugate and agonist are each comprised in an amount such that, in combination with the other, are effective to produce the immune response in a human or animal subject in need of immunostimulation. | 2012-02-16 |
20120039917 | IMMUNOMODULATING ACTIVITIES - Composition of isoflavonoids and chromanols and use of them as immunomodulators and as inhibitors of T-cell or T-lymphocyte proliferation. Treatment of disorders involving abnormal proliferation or activity of T cells. Formula (I) where A is hydrogen or optionally substituted phenyl and R1 represents hydroxy, alkoxy, halo or an ester and R2-R8 represent hydogen, hydroxy, alkyl etc. | 2012-02-16 |
20120039918 | Composition for Enhancing Immunity Containing Plant Stem Cell Line Derived from Cambium of Panax Ginseng Including Wild Ginseng or Ginseng as an Active Ingredient - The present invention relates to a composition for enhancing immunity, comprising one or more of the following: a homogenous cell line, and a lysate, an extract and a culture medium thereof as an active ingredient. The homogenous cell line, the lysate, the extract and the culture thereof according to the present invention, which are derived from a natural product, minimize adverse side effects of prior immune enhancing agents and safe for the human body. Further, they effectively increase the activity of NK cells responsible for innate immunity, as well as increase the proliferation rate of lymph node cells when the cells were re-exposed to an antigen in a specific immune reaction to enhance acquired immunity, and thus are useful as an immune enhancing agent. In particular, the homogenous cell line, the lysate, the extract, and the culture thereof according to the present invention also effectively increase the number of hone marrow cells, thus are not only used as an adjuvant in an immune reaction, but also used in the prevention and treatment of anemia through hematopoiesis. | 2012-02-16 |
20120039919 | DIABETES DIAGNOSTIC, PROPHYLACTIC, AND THERAPEUTIC COMPOSITIONS AND METHODS - As described below, the present invention features compositions and methods featuring Pdx-1 polypeptides and fragments thereof for the diagnosis, prevention and treatment of diabetes. | 2012-02-16 |
20120039920 | HYDROPHOBIC MONOMERS, HYDROPHOBICALLY-DERIVATIZED SUPPORTS, AND METHODS OF MAKING AND USING THE SAME - A composition is disclosed comprising a hydrophobic monomer having the structure: CH | 2012-02-16 |
20120039921 | POULTRY VIRAL MATERIALS AND METHODS RELATED THERETO - The present invention provides materials and methods for researching poultry viruses, particularly for researching infectious bronchitis viruses in poultry. Also provided are materials and methods useful for reducing the economic impact that infectious bronchitis disease has on poultry production. In one aspect of the invention, there are provided nucleic acids, amino acids and related materials and compositions useful for combating infectious bronchitis virus in poultry. | 2012-02-16 |
20120039922 | METHOD AND PEPTIDE FOR REGULATING CELLULAR ACTIVITY - Method and peptide for regulating cellular activity includes a panel of synthesized peptides that have biological effects on inhibiting or enhancing cellular activity. Selected peptides can be used as therapy to reduce and/or inhibit, or initiate and/or enhance, an inflammatory response in a subject. | 2012-02-16 |
20120039923 | Modified HIV-1 Envelope Proteins - The present invention relates to modified HIV-1 envelope proteins where one or more N-glycosylation sites have been deleted or modified, which produce a broadly cross reactive neutralizing response, their methods of use and antibodies which bind to these proteins. The invention also provides for nucleic acids, vectors, antibodies and pharmaceutical compositions that comprise said modified HIV-1 envelope proteins. | 2012-02-16 |
20120039924 | COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF INFLAMMATORY BOWEL DISEASE - Compositions and methods for the therapy and diagnosis of Inflammatory Bowel Disease (IBD), including Crohn's Disease and Ulcerative Colitis, are disclosed. Illustrative compositions comprise one or more bacterial polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of IBD. | 2012-02-16 |
20120039925 | TUBERCULOSIS TB VACCINE TO PREVENT REACTIVATION - The present invention discloses a vaccine or immunogenic composition that can be administered to latently infected individuals to prevent reactivation of latent tuberculosis infection caused by species of the tuberculosis complex microorganisms ( | 2012-02-16 |
20120039926 | Compositions and Methods for Modulating Immunogenic Responses by Activating Dendritic Cells - The conjugated peptide constructs described herein can be used to induce production of dendritic cells that generate cytokines. The vaccine-bearing dendritic cells can be administered to induce T cell mediated immune modulating responses. | 2012-02-16 |
20120039927 | USE OF EXTRACTS OF PEZIZACEAE IN THE PREVENTION AND/OR TREATMENT OF SENILE CATARACTS - The invention provides methods for treating and/or preventing the recurrence of a senile cataract, and/or for inhibiting the development of a senile cataract and/or an incipient senile cataract, in a human or animal subject. The invention further provides nutraceutical compositions suited for the same, derived from an extract of truffles (Pezizaceae). The compositions comprise the extract in a therapeutically sufficient amount for the treatment and/or prophylaxis of a senile cataract in a human and/or animal subject. | 2012-02-16 |
20120039928 | Medicinal plants extract using processing of herbal medicine and composition of skin external application comprising the same - The present invention relates to an extract of a processed herbal medicinal plant and a composition for skin external application which contains the extract. More specifically, the composition for skin external application contains an extract of processed herbal medicinal plant, prepared through a method comprising the steps of: (a) processing an herbal medicinal plant by a process of boiling, steaming, roasting, baking or heating the medicinal plant or a combination of two or more of these processes; (b) obtaining an extract of the processed medicinal plant. The composition shows an improved antioxidant effect. | 2012-02-16 |
20120039929 | NOVEL THERAPY FOR LYSOSOMAL ENZYME DEFICIENCIES - The present invention provides a therapeutic delivery system comprising an extracted yeast cell wall comprising beta-glucan, a payload trapping molecule and a payload molecule, wherein the payload molecule and the payload trapping molecule are soluble in the same solvent system wherein the payload molecule supplements the function of the deficient lysosomal enzyme. The invention further provides methods of making and methods of using the therapeutic delivery system. | 2012-02-16 |
20120039930 | BASE, PRODUCTS CONTAINING THE SAME, PREPARATION METHODS AND USES THEREOF - The present invention concerns a base characterized in that it is prepared by the following steps : (a) partial bio-hydrolysis of raw materials rich in precursors, and (b) thermal reaction steps of the resulting product from (a). Said base can be prepared with a further step, which is a subsequent or simultaneous fermentation of the resulting product from step (a). | 2012-02-16 |
20120039931 | DNA COMPOSITION ENCODING AN IMMUNOGENIC VEGF RECEPTOR PEPTIDE AND METHODS OF USE THEREOF - A method of inhibiting endothelial cell proliferation in a mammal is provided. The method comprises the step of administering to the mammal an effective immunological response eliciting amount of a DNA composition comprising a DNA construct operably encoding a VEGF receptor polypeptide and a pharmaceutically acceptable carrier therefor, whereby said mammal exhibits an immune response elicited by vaccine and specific to proliferating endothelial cells. The methods of this invention inhibit vascular endothelial cell proliferation in the tumor micro-environment. Angiogenesis inhibition and subsequent decrease in tumor growth and dissemination is achieved. | 2012-02-16 |
20120039932 | Lentiviral Vectors Pseudotyped with a Sindbis Virus Envelope Glycoprotein - Lentiviral vector particles comprising a Sindbis virus E2 glycoprotein variant and a lentiviral vector genome comprising a sequence of interest are provided. A lentiviral vector particle comprising: (a) an envelope comprising a Sindbis virus E2 glycoprotein variant; and (b) a lentiviral vector genome comprising a sequence of interest; wherein the E2 glycoprotein variant facilitates infection of dendritic cells by the lentiviral vector particle, and wherein the E2 glycoprotein variant has reduced binding to heparan sulfate compared to a reference sequence (HR strain). | 2012-02-16 |
20120039933 | METHODS FOR ONE-DOSE INTRADERMAL DELIVERY FOR NON-LIVE TRIVALENT INFLUENZA VACCINE - The invention relates to methods for one-dose influenza vaccine for intradermal delivery of a trivalent, non-live influenza antigen preparation, particularly a split influenza preparation. | 2012-02-16 |
20120039934 | ADJUVANT-SPARING MULTI-DOSE INFLUENZA VACCINATION REGIMEN - An influenza vaccine is administered by a multi-dose regimen, in which (i) a first dose is administered with an adjuvant and (ii) a later dose is administered either without an adjuvant or with a different adjuvant. Thus the invention provides the benefits of a two-dose regimen without also doubling the supply need for a given adjuvant. | 2012-02-16 |
20120039935 | METHODS OF TREATING MEASLES INFECTIOUS DISEASE IN MAMMALS - The invention provides for a measles vaccine utilizing a human codon-optimized polynucleotide encoding a measles virus polypeptide, such as HA or F protein. Optionally, the vaccine is administered with an adjuvant and is especially useful for immunizing an infant mammal. | 2012-02-16 |
20120039936 | INTERGENIC REGIONS AS INSERTION SITES IN THE GENOME OF MODIFIED VACCINIA VIRUS ANKARA (MVA) - The present invention relates to novel insertion sites useful for the integration of exogenous sequences into the Modified Vaccinia Ankara (MVA) virus genome. The present invention further provides plasmid vectors to insert exogenous DNA into the genome of MVA. Furthermore, the present invention provides recombinant MVA comprising an exogenous DNA sequence inserted into said new insertion site as medicine or vaccine. | 2012-02-16 |
20120039937 | INDUCTION OF AN IMMUNE RESPONSE AGAINST DENGUE VIRUS USING THE PRIME-BOOST APPROACH - The invention relates to methods for the induction of an immune response to dengue virus. The method of inducing an immune response against dengue virus comprises administration of a non-replicating immunogen followed by a boost with a tetravalent live attenuated viral vaccine. Another aspect of the inventive subject matter is a method of inducing an immune response against dengue virus using a heterologous prime-boost regimen with the priming immunogen comprising a DNA expression system, an adenovirus expression vector or a Venezuelan equine encephalitis virus replicon system and the boosting immunogen comprising the same without the DNA expression system. Each expression system contains DNA sequences encoding dengue viral proteins. | 2012-02-16 |
20120039938 | COMPOSITION COMPRISING THE POLYPROTEIN NS3/NS4 AND THE POLYPEPTIDE NS5B OF HCV, EXPRESSION VECTORS INCLUDING THE CORRESPONDING NUCLEIC SEQUENCES AND THEIR THERAPEUTIC USE - The invention relates to a peptidic compound containing a polyprotein NS3/NS4 of a hepatitis C virus and a polypeptide NS5b of hepatitis C virus. Said invention also relates to expression vectors such as adenovirus and poxyvirus in which nucleic sequences coding for the polyprotein NS3/NS4 and the polypeptide NS5b. The inventive compound can be used for a therapeutic application. | 2012-02-16 |
20120039939 | COMPOSITIONS AND METHODS FOR VACCINE AND VIRUS PRODUCTION - The present invention features methods of producing immunogenic compositions and viruses, methods of treating and preventing viral infection, and methods of producing an immune response using cells that express a polypeptide selected from the group consisting of: cdk13, siat7e, Iama4, cox15, egr1, gas6, map3k9, and gap43, and a virus. | 2012-02-16 |
20120039940 | METHODS FOR TREATING UTERINE DISORDERS - A method for treating uterine disorders, including hyperplasic, hypertonic, cystic and/or neoplastic uterine gland tissue by local administration of a botulinum toxin to or to the vicinity of the afflicted uterine tissue. | 2012-02-16 |
20120039941 | ENGINEERED BOTULINUM NEUROTOXIN - The present invention provides a novel modified BoNT/E catalytic domain and methods of use thereof. In one embodiment, the light chain residue 224, or a residue corresponding to residue 224, of the modified BoNT/E catalytic domain has been altered to be aspartic acid or glutamic acid. The modified catalytic domain cleaves SNAP23 but does not cleave SNAP29 or SNAP47, providing novel methods of treating diseases including without limitation, asthma, CF, chronic obstructive pulmonary, gastric acid efflux and inflammation, immune disorders with a cytokine component or cancers with a cytokine component. | 2012-02-16 |
20120039942 | OUTER MEMBRANE VESICLES AND USES THEREOF - The present invention discloses a Gram negative bacterium in which the expression of a protein involved in LPS transport to the outer membrane is functionally down-regulated such that the level of LPS in the outer membrane is decreased compared to a wild-type Gram negative bacterium. Down regulation of Imp and MsbA proteins can result in such a bacterium. Outer membrane vesicle preparations derived from the Gram negative bacterium of the invention can be used in vaccines to provide protection against bacterial infection. | 2012-02-16 |
20120039943 | FACTORS - A method for determining a prognosis for benefit for a cancer patient receiving immunotherapy treatment involving (a) measuring a level of platelets and haemoglobin in a sample from the cancer patient, and (b) comparing the level of platelets in the sample to a reference level of platelets and comparing the level of haemoglobin in the sample to a reference level of haemoglobin, wherein a lower level of platelets and higher level of haemoglobin in the sample correlates with increased benefit to the patient. | 2012-02-16 |
20120039944 | WHEY AND THYMUS FUNCTION - The present invention generally relates to the field of nutrition and health. In particular, the present invention provides a composition that can be used to maintain or improve thymus health. One embodiment of the present invention is the use of whey or at least one protein fraction thereof for the preparation of a composition to maintain or improve thymus function. | 2012-02-16 |
20120039945 | Methods Of Immune Modulation - The present invention provides compounds and compositions thereof that modulate the immune system. | 2012-02-16 |
20120039946 | IMMUNOPOTENTIATING COMPOSITION AND PROCESS FOR PRODUCING SAME - Disclosed is an immunopotentiating composition comprising an effective immunostimulating substance which can activate natural immunity and a subsequent immunity mediated by lymphocytes without causing any damage to cells. Specifically disclosed is an immunopotentiating composition which is characterized by comprising, as an active ingredient, an immunostimulating substance produced by decomposing at least one bacterium selected from an MRE symbiotic bacteria group consisting of | 2012-02-16 |
20120039947 | METHODS AND COMPOSITIONS FOR TREATING PSORIASIS - Methods and compositions including anthralin for treating psoriasis of the skin and scalp are described. | 2012-02-16 |
20120039948 | Instant Vesicular Product - A powder of reversed vesicles, which comprises one or more non-ionic surfactants and optionally a lipophilic stabilising factor and a bio-active agent, is provided. The product is prepared by making a dispersion of reversed vesicles in a suitable apolar vehicle, which vehicle is subsequently removed. In admixture with one or more excipients the product can be incorporated in compositions. | 2012-02-16 |
20120039949 | Stable Solid Formulations of GC-C Receptor Agonist Polypeptides Suitable for Oral Administration - Solid, stable formulations of GC-C receptor agonist polypeptide suitable for oral administration are described herein as are methods for preparing such formulations. The GC-C receptor agonist polypeptide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug. | 2012-02-16 |
20120039950 | COLOSTRUM COMPOSITION - The present invention relates to a composition comprising colostrum and at least one agent selected from the group of hydrocolloids, wherein said colostrum and at least one agent are bioconjugated. The bioconjugated composition has improved properties compared to colstrum compositions that are not bioconjugated with a hydrocolloid agent. The composition may be used in a variety of settings, for example for topical application for treating skin diseases and skin conditions. The present invention thus also relates to use of the composition and to a method for the preparation of the composition. | 2012-02-16 |
20120039951 | COMPOSITIONS AND METHODS FOR ENHANCING PHYSIOLOGICAL PERFORMANCE AND RECOVERY TIME - Provided are methods for enhancing exercise (e.g., intense, eccentric, elevated temperature, repetitive, aerobic, and high altitude) performance, comprising administering electrokinetically-altered aqueous fluids comprising an ionic aqueous solution of stably configured charge-stabilized oxygen-containing nanostructures predominantly having an average diameter of less than 100 nanometers. In certain aspects, enhancing exercise performance comprises at least one of: reducing plasma inflammatory cytokines (e.g., IFN-alpha, ENA-78 and BDNF); ameliorating muscle/tendon damage or enhancing muscle/tendon recovery; reducing biomarkers of exercise-induced muscle injury (e.g., CK, plasma myoglobin); ameliorating exercise induced tendinosis, tendonitis, tenosynovitis, avulsion, and tendon strain associated with chronic repetitive movement or enhancing recovering therefrom; increasing VO | 2012-02-16 |
20120039952 | COMPOSITIONS, METHODS & SYSTEMS FOR RESPIRATORY DELIVERY OF TWO OR MORE ACTIVE AGENTS - Compositions, methods and systems are provided for pulmonary or nasal delivery of two or more active agents via a metered dose inhaler. In one embodiment, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a co-suspension within the suspension medium. | 2012-02-16 |
20120039953 | RILUZOLE AQUEOUS SUSPENSIONS - Physically and chemically stable aqueous suspensions of riluzole are disclosed together with the manufacturing methods thereof. Such aqueous suspensions comprise riluzole in particle form and at least a wetting agent, preferably a surfactant. Riluzole is in amounts from about 0.1% to about 20% w/v and has an average particle size lower than 200 μm; such suspensions are devoid of the known local (mouth) anaesthetic effects of riluzole. | 2012-02-16 |
20120039954 | METHOD OF TREATING INSOMNIA - A method of treating insomnia comprising administering to a subject a formulation including zaleplon, wherein the formulation is adapted to release the zaleplon after a lag time of at least about one hour after administration of the formulation, and during which substantially no drug substance is released; provide a time of peak plasma concentration of about 3 hours to about 6 hours after administration; provide an elimination half-life after the time of peak plasma concentration of about 0.5 hours to about 0.3 hours; and provide an area under the curve of about 70 ng·h/mL to about 90 ng·h/mL. | 2012-02-16 |
20120039955 | Treatment of Diabetes with Pancreatic Endocrine Precursor Cells - The present invention provides a method for lowering blood glucose levels in an animal by transplanting a population of pancreatic endocrine precursor cells into an animal. | 2012-02-16 |
20120039956 | DRY STORAGE STABILIZING COMPOSITION FOR BIOLOGICAL MATERIALS - The present invention includes compositions and drying methods for preserving sensitive bioactive materials, such as peptides, proteins, hormones, nucleic acids, antibodies, drugs vaccines, yeast, bacteria (probiotic or otherwise), viruses and/or cell suspensions, in storage. The compositions include a carbohydrates component and a glass enhancer component, wherein the carbohydrate component includes a mixture of di-, oligo- and polysaccharides and the glass enhancer includes ions of organic acid and protein hydrolysates. The composition is prepared by dispersing all the solid components in a solution and then snap-frozen to form small beads, strings or droplets. The preferred drying method of the frozen beads, strings or droplets is initiated by a short purging and structure stabilizing step of the frozen particles under a vacuum pressure of less than <2000 mTORR followed by a primary drying step under vacuum pressure of more than >2000 mTORR and at a desired temperature. During the secondary and final drying step of the material a full vacuum pressure and elevated temperature are applied, to achieve a final desirable water activity of the dry material. | 2012-02-16 |
20120039957 | OPTIMIZED NIACIN COMPOSITIONS IN PHARMACEUTICAL PRODUCTS - The present invention includes compositions and methods related to forms of niacin with enhanced in-vivo absorption and bioavailability. Such enhanced delivery of niacin in the presence of food may be achieved by size reduction of crystalline niacin, use of amorphous forms of niacin, and/or pH modulation in the presence on organic acids. | 2012-02-16 |
20120039958 | COMPOSITIONS AND METHODS FOR TREATMENT OF TAUPATHY - Provided are electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient for treating an inflammatory neurodegenerative condition or disease (e.g., a taupathy) or at least one symptom thereof. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ionic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for modulating phosphorylation of tau protein. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membrane potential and/or conductance, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids and therapeutic compositions. | 2012-02-16 |
20120039959 | Anti-Adhesion Alginate Barrier of Variable Absorbance - Described are mono- and bi-layer alginate post-surgical anti-adhesion barriers with tailored absorption profiles and non-migrating characteristics. Muco-adhesive properties of alginates in their solid state are used to localize the device, and lubricious properties of alginates in their liquid state are used to mitigate adhesion formation during wound healing. In addition, the design of the implant can be selected such that the crosslinking agent is released from the device under specific conditions and the absorbance profile modified. A medicinal agent may optionally be incorporated. | 2012-02-16 |
20120039960 | DENTAL ANESTHETIC COMPRISING TETRACAINE AND A VASOCONSTRICTOR FOR INTRANASAL ADMINISTRATION - The present invention relates to tetracaine based anesthetic formulations and methods of use thereof. The invention further relates to topical formulations of tetracaine and methods of topically anesthetizing body tissues. The present invention also relates to tetracaine based dental anesthetic formulations and methods for anesthetizing the maxillary dental arch using these formulations. | 2012-02-16 |
20120039961 | IMPLANT AND THERAPEUTIC COMPOSITION FOR TREATING DAMAGE AND/OR DISEASES RELATING TO THE HUMAN ANIMAL MUSCULOSKELETAL SYSTEM - An implant includes a support material, cartilage cells and/or precursor cells thereof, and a cartilage-specific collagen type. A method for preparing the implant, to a therapeutic composition, includes cartilage cells and/or precursor cells thereof and a cartilage-specific collagen type. The implant and the therapeutic composition are suitable in particular for treating damage and/or diseases relating to the human and/or animal musculoskeletal system. | 2012-02-16 |
20120039962 | Pharmaceutical Compositions - Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided. | 2012-02-16 |
20120039963 | 3-(2-Dimethlaminomethyl Cyclohexyl)Phenol Retard Formulation - A pharmaceutical dosage form for controlled release of the active substance 3-(2-dimethylaminomethylcyclohexyl)-phenol, preferably (1R,2R)-3-(2-dimethylaminomethylcyclohexyl)-phenol, or a pharmaceutically acceptable salt thereof, which dosage form (i) in vivo produces a peak plasma level of the active substance after 2 to 10 hours, and/or (ii) in vitro releases 3.0 to 37 percent by weight of the active substance originally contained in the dosage form after one-half hour, 5.0 to 56 percent by weight after one hour, 10 to 77 percent by weight after two hours, 15 to 88 percent by weight after 3 hours, at least 30 percent by weight after six hours, at least 50 percent by weight after 12 hours, at least 70 percent by weight after 18 hours, and at least 80 percent by weight after 24 hours when measured according to the European pharmacopoeia using a blade mixer in preferably 900 ml of a buffer solution at a pH value of 6.9, a temperature of 37° C., and 75 rpm. | 2012-02-16 |
20120039964 | NOVEL FORMULATIONS OF FAT-SOLUBLE ACTIVE INGREDIENTS WITH HIGH BIOAVAILABILITY - The present invention relates to formulations of a pharmacological effective fat-soluble active ingredient with a high bioavailability of said fat-soluble active ingredient as well as to their manufacture and use as dietary supplement, food, feed, personal care product and/or pharmaceutical. Such formulations are those which when dissolved, dispersed or diluted in/with water have an extinction E1/1 at a wavelength in the range of from 200 to 800 nm, preferably in the range of from 250 to 600 nm, more preferably in the range of from 250 to 500 nm, more preferably in the range of from 370 to 485 nm, of ≧380, preferably of ≧600, most preferably ≧900. In preferred embodiments of the formulations of the present invention such formulations show an extrusion loss of fat-soluble active ingredient of ≦30% when pressed to tablets. | 2012-02-16 |
20120039965 | ENHANCED ANTIMICROBIAL ACTIVITY COMPOSITIONS OF BLENDS OF PLANT ESSENTIAL OILS - Antimicrobial compositions based on a combination or blend of plant essential oils is of enhanced antimicrobial effectiveness; by adding to the combination of at least two plant essential oils, and preferably adds a small but antimicrobial enhancing effective amount of an enhancer selected from the group consisting of polyionic organic enhancers and polyionic inorganic enhancers. One preferred blended oil composition is a mixture of plant essential oils wherein at least one of the oils is oregano oil. The oil blend is used as a major component in the finished product anti-microbial. | 2012-02-16 |
20120039966 | Rinse-Off Care Products and Consumer Product Line-ups Comprising Same - Consumer product line-ups are provided that include a rinse-off care product that may be used in conjunction with a traditional leave-on antiperspirant or deodorant product to better manage underarm malodor. | 2012-02-16 |
20120039967 | Low Rub-Off Compositions - Low rub-off compositions comprising a silicon-based particle that encapsulates a colorant are described. The compositions can comprise a color generating component and are suitable to immediately impart an even color to skin when topically applied. | 2012-02-16 |
20120039968 | ANTIPERSPIRANT PRODUCTS COMPRISING ACTIVE ANTIPERSPIRANT COMPOUNDS SURFACE TREATED WITH HYDROPHOBIZING AGENTS AND METHODS FOR MANUFACTURING THE SAME - Antiperspirant products comprising active antiperspirant compounds surface treated with hydrophobizing agents and methods for manufacturing such products are provided. In accordance with an exemplary embodiment, an antiperspirant product comprises a hydrophobic carrier and an active antiperspirant compound with a coating of a hydrophobizing agent. | 2012-02-16 |
20120039969 | SWELLABLE DOSAGE FORM COMPRISING GELLAN GUM - A novel dosage form. The dosage form is presented in particulate form and before oral ingestion the particulate material is subjected to an aqueous medium, whereby it is converted to a semi-solid form by swelling or gelling of one or more of the components, especially of a gellan gum, of the particulate matter. The invention also relates to a vehicle for oral administration of one or more active substances, the vehicle comprising a gellan gum arranged in a configuration allowing optimal water diffusion so that upon addition of a predetermined amount of an aqueous medium, without the necessity of applying shear forces or other mixing forces, within a time period of 5 minutes or less swells and/or gels and the texture of the swelled vehicle being similar to that of a soft pudding and having a viscosity of at least about 10,000 cps as measured by a Brookfield Viscometer with a #4 LV spindle at 6 rpm and at 20-25° C. In one embodiment of the invention, the particulate matter can be molded into a desired shape or pressed onto a dispensing unit such as a spoon. | 2012-02-16 |
20120039970 | READY-TO-USE, STABLE SUSPENSION OF PARTIALLY AMORPHOUS CAROTENOID PARTICLES - The present invention relates to a ready-to-use stable suspension of partially amorphous carotenoid particles, a process for production thereof and also use thereof as additive to animal feeds, foods and food supplements and also cosmetic and pharmaceutical compositions. | 2012-02-16 |
20120039971 | Solid Powder Cosmetic And Method For Producing The Same - An object of the present invention is to provide a solid powder cosmetic having an excellent effect of preventing makeup running and oily shining, and having a satisfactory long-lasting makeup effect. A solid powder cosmetic comprising: a powder component, an oily component as a binder, and an amide mixture obtained by amidating a mixture of hexamethylenediamine and bisaminomethylcyclohexane with hydrogenated castor oil fatty acids. It is suitable for the solid powder cosmetic that an amount of the amide mixture is 1.0% to 15% by mass. It is suitable for the solid powder cosmetic to comprise 1% to 20% by mass of spherical poly(meth)acrylate particles as the powder component. It is suitable for the solid powder cosmetic to further comprise an organically modified clay mineral in an amount of 1.0% to 15% by mass as a total amount with the amide mixture. It is also suitable for the solid powder cosmetic to comprise 5% to 97% by mass of fluorine compound-treated powder as the powder component. | 2012-02-16 |
20120039972 | OILY COMPOSITION AND ROD-SHAPED PREPARATION - An oily composition which gives a preparation for lip through solidification, characterized by comprising: (A) an N-acylamino acid derivative containing, for example, two N-acylglutamic acid dialkylamide; (B) a polyamide resin containing, for example, (dimer dilinoleic acid bisdioctadecylamide/ethylenediamine) copolymer; and (C) a liquid oil containing, for example, dimer acid esters; and which, upon solidification to give a preparation for lip, can exhibit sufficient transparency and further can give a satisfactory use feeling. | 2012-02-16 |
20120039973 | Composition and method of time releasing essential oils for animal repellency and pesticide use - The invention is a method of releasing essential oils over at least 30 days which includes encapsulating one or more essential oils in one or more carbohydrate and one or more protein. Additional embodiments include pesticides and/or additional repellents. | 2012-02-16 |
20120039974 | Quaternary Ammonium Caprylyl Glycol Disinfectant Wipes - A disinfectant wipe and disinfectant composition which exhibits exceptional antimicrobial activities as a result of the synergistic combination of a quaternary ammonium salts and 1,2-alkandiol is provided. The wipe is pre-impregnated with a disinfectant composition which comprises a quaternary ammonium salt, a 1,2-alkanediol with 5-10 carbon atoms, a glycol ether, a surfactant, a pH regulating agent, and water, and optionally alcohol. A method of preparation and a process for disinfecting a surface with the wipe composition are also provided. | 2012-02-16 |
20120039975 | NANOCOMPOSITE MATERIALS HAVING ELECTROMAGNETIC-RADIATION BARRIER PROPERTIES AND PROCESS FOR OBTAINMENT THEREOF - Nanocomposite materials having electromagnetic-radiation barrier properties comprising layered nanoadditives with or without organic and/or inorganic surface modification; and a polymeric matrix, process for obtainment thereof and use of said nanocomposite materials in applications of packaging, greenhouse films, coatings, etc. | 2012-02-16 |
20120039976 | Controlling zoonotic disease vectors from insects and arthropods using preconidial mycelium and extracts of preconidial mycelium from entomopathogenic fungi - The present invention utilizes extracts of the pre-sporulation (preconidial) mycelial stage of entomopathogenic fungi as insect and arthropod attractants and/or pathogens and can be employed to limit the zoonotic diseases they transmit. The fungus can be cultivated on grain, wood, agricultural wastes or other cellulosic material and extracts can be made thereof. More than one fungus and substrate can be used in combination with one or more antimicrobial, antiprotozoal, antiviral, and genetically modified agents that result in reduced spread of contagions and lessens the damage they inflict on animals, and plants. | 2012-02-16 |
20120039977 | MICROBE MITIGATING ARCHITECTURAL BARRIERS, COMPOSITIONS FOR FORMING SUCH BARRIERS AND RELATED METHODS - The invention includes a microbe-mitigating architectural barrier that includes a barrier forming material, and at least one biocide. The barrier forming material may be a bitumen product, an elastomeric polymer and combinations thereof. The microbe-mitigating architectural barrier may be formed by applying an emulsion composition directly to an architectural surface, or it may be preformed and adhered or otherwise secured to the architectural surface in the form of a sheet or film. | 2012-02-16 |
20120039978 | Novel Anti-Viral Method - The invention provides a method of reducing viral infectivity in a sample compnsing contacting the sample with a earner matrix wherein lipids are attached to the carrier matrix, and wherein at least one virus-specific agent is attached to the lipids The virus-specific agent is capable of binding to at least one viral component The virus specific agent may be a receptor The earner matrix may be a silica particle, which may be coated with a lipid bilayer The invention further provides a method of inactivating a virus comprising contacting the virus with a earner matrix wherein lipids are attached to the earner matrix, and wherein at least one receptor is attached to the lipids, binding the receptor to at least one viral receptor-binding protein, and activating at least one viral fusion protein, wherein activation inactivates the virus, and releases the virus from the earner matrix | 2012-02-16 |
20120039979 | INSECT CONTROL SUBSTANCE THAT CAN BE APPLIED TO A SURFACE - An insect control substance for controlling certain flying insect pests in proximity to the substance includes a rubber crumb carrier having a plurality of rubber particles and a volatile hydrophobic semiochemical for attracting certain flying insect pests absorbed within the rubber particles forming a discontinuous phase of the substance. The insect control substance also includes a body of water forming a continuous phase of the substance within which the discontinuous phase is suspended. When the insect control substance is applied to an application surface the discontinuous phase is exposed to the surrounding air and the semiochemical within the rubber particles evaporates into the air around the application surface and attracts the flying insect pests to the rubber crumb carrier to facilitate control of the flying insect pests. | 2012-02-16 |
20120039980 | COMPOSITIONS AND SYSTEMS FOR FORMING CROSSLINKED BIOMATERIALS AND ASSOCIATED METHODS OF PREPARATION AND USE - Methods of preventing adhesion between issues are provided that utilizes in situ crosslinked biomaterials. The biomaterial contains at least the crosslinked product of two biocompatible, non-immunogenic components having reactive groups thereon, with the functional groups selected so as to enable inter-reaction between the components, i.e., crosslinking. Exemplary uses for the crosslinked compositions include preventing adhesions following surgery or injury, and preventing scar tissue formation. | 2012-02-16 |
20120039981 | Chewing Gum And Particulate Material For Controlled Release Of Active Ingredients - A particulate material for controlled release of active ingredients includes a combination of one or more active ingredients, including nicotine, and an inorganic mineral filler, in which the active ingredient is reversibly absorbed into and/or adsorbed onto the inorganic mineral filler, and the BET specific surface area of the inorganic mineral filler is above 15 m | 2012-02-16 |
20120039982 | Bio-Sheet for Eye Tissue Repair - A bio-sheet applied on the eye tissue repair is disclosed. The bio-sheet comprises a biodegradable substrate formed of fish scales and has an epithelial cell layer formed thereon, wherein the fish scales are bony scales. | 2012-02-16 |
20120039983 | AMPHIPHILIC MACROMOLECULE-LIPID COMPLEXES - The invention provides amphiphilic macromolecule (AM)-lipid complexes, methods of making the complexes, and methods of using the complexes. | 2012-02-16 |
20120039984 | GLYCOPEPTIDE AND USES THEREOF - A glycolipopeptide comprising a carbohydrate component, a peptide component and a lipid component, for use as a therapeutic or prophylactic vaccine. Also provided are monoclonal and polyclonal antibodies that recognize the glycolipopeptide of the invention, as well as uses thereof. | 2012-02-16 |
20120039985 | DENDRITIC CELL MODULATION IN POST-ISCHEMIC WOUNDS - Compositions and methods useful for targeted depletion or modulation of dendritic cells are provided. The compositions and methods can be used to promote healing of ischemia-related injury, including ischemia-reperfusion injury. Disclosed are a variety of dendritic cell-targeted toxins, bone morphogenetic protein 7 (BMP7) agonists, and dendritic cell-targeted transforming growth factor beta 1 (TGF-β1) antagonists, all useful in practicing methods of the invention. The inventive compositions and methods can be used in the treatment of various conditions including myocardial infarction, stroke, and critical limb ischemia. | 2012-02-16 |
20120039986 | COMPOSITIONS AND METHODS FOR SIRNA INHIBITION OF ANGIOPOIETIN 1 AND 2 AND THEIR RECEPTOR TIE2 - RNA interference using small interfering RNAs which are specific for mRNA produced from the Ang1, Ang2 or Tie2 genes inhibits expression of these genes. Diseases which involve Ang1, Ang2 or Tie2 mediated angiogenesis, such as inflammatory and autoimmune diseases, diabetic retinopathy, age related macular degeneration and many types of cancer, can be treated by administering the small interfering RNAs. | 2012-02-16 |
20120039987 | NIOSOME HAVING METAL PORPHYRIN COMPLEX EMBEDDED THEREIN, PROCESS FOR PRODUCING THE SAME AND DRUG WITH THE USE THEREOF - A niosome having a metalloporphyrin complex embedded therein comprising a cationized metalloporphyrin complex and a niosome-forming substance. The niosome having a metalloporphyrin complex embedded therein has an SOD activity, can interact with superoxide anionic radicals (O | 2012-02-16 |
20120039988 | CANCER-TARGETING PEPTIDES AND USES THEREOF IN CANCER THERAPY - Cancer-targeting peptides and uses thereof in cancer therapy. | 2012-02-16 |
20120039989 | ERYTHROCYTE-BINDING THERAPEUTICS - Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired. Fusions with targeting peptides direct the fusions to the target, for instance a tumor, where the erythrocyte-binding ligands reduce or entirely eliminate blood flow to the tumor by recruiting erythrocytes to the target. | 2012-02-16 |
20120039990 | Liposome Compositions and Methods of Use Thereof - The present application relates to compositions comprising and methods of using a liposome comprising a pHLIP polypeptide, wherein a lipid bilayer of the liposome is substantially free of the pHLIP polypeptide. | 2012-02-16 |
20120039991 | USE OF APOPTOSIS INHIBITING COMPOUNDS IN DEGENERATIVE NEUROLOGICAL DISORDERS - The invention provides methods and compositions for localized delivery of a vector comprising a therapeutic agent to a specific region of the brain associated with a neurodegenerative diseases that is characterized by an excess buildup of buildup of intracellular protein aggregates. In particular, the invention provides methods and compositions used to deliver an adeno-associated virus vector (AAV) comprising a nucleotide sequence encoding an inhibitor of apoptosis protein (IAP) to cells in the region. | 2012-02-16 |
20120039992 | COMPOSITIONS OF POLYMERIC MYRCENE - The invention relates to compositions and formulations comprising polymeric myrcene. More particularly, the invention relates to compositions comprising an isolated fraction of polymeric myrcene in a hydrophobic carrier and formulations which maintain the biological activity of the active polymer. | 2012-02-16 |
20120039993 | Detection of Gene Expression - An oligonucleotide, primer or probe comprises the nucleotide sequence of any of SEQ ID NO. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 44, 61, 62 or 63. The oligonucleotide, primer or probe is useful for the detection of the methylation status of a gene. The oligonucleotides find application in the diagnosis and treatment of cancer. | 2012-02-16 |
20120039994 | VACCINE COMPOSITION CONTAINING SYNTHETIC ADJUVANT - Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier. | 2012-02-16 |
20120039995 | ARSENIC COMPOUNDS, THEIR PREPARATION METHODS AND USES THEREOF - Arsenic compounds of general formula (I), their preparation methods, the pharmaceutical compositions containing the compounds, and their uses in the manufacture of medicaments for treating cancer, particularly leukemia, are disclosed. | 2012-02-16 |
20120039996 | USES OF RED YEAST RICE IN TREATING DENGUE VIRUS INFECTION - This invention provides a method of using red yeast rice fermented product to treat a subject having a disease caused by dengue virus. In one embodiment, the red yeast rice is prepared with the yeast | 2012-02-16 |
20120039997 | METHODS OF TREATING HYPERTRIGLYCERIDEMIA - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. | 2012-02-16 |
20120039998 | PROCESS OF MANUFACTURING A STABLE SOFTGEL CAPSULE CONTAINING MICROENCAPSULATED PROBIOTIC BACTERIA - A softgel capsule containing microencapsulated probiotic bacteria is manufactured such that the softgel capsule is stable for at least about 24 months at room temperature. | 2012-02-16 |
20120039999 | PHARMACEUTICAL COMPOSITIONS OF METABOTROPIC GLUTAMATE 5 RECEPTOR (MGLU5) ANTAGONISTS - Pharmaceutical compositions of metabotropic glutamate 5 receptor (mGlu5) antagonists or a pharmacologically acceptable salt thereof are disclosed. The compositions contain the therapeutic active compound with non-ionic polymer and ionic polymer, binder and fillers in either matrix pellet, matrix tablet or coated pellets. The compositions provide a pH-independent in vitro release profile with NMT 70% in one hour, NMT 85% in 4 hour, and NLT 80% in 8 hours. The compositions are useful for the treatment of CNS disorders, such as Treatment-Resistant Depression (TRD) and Fragile X Syndrome. | 2012-02-16 |
20120040000 | PEPTIDE PHARMACEUTICAL FOR ORAL DELIVERY - Acid-containing oral pharmaceutical compositions are provided wherein the pharmaceutical active agents are peptide compounds (i.e., those that include a plurality of amino acids and at least one peptide bond in their molecular structures). Certain barrier layers and/or particulate coated acid are used to reduce any adverse interactions that might otherwise occur between the acid of the compositions and other components of the composition. Use of these barrier layers and/or use of particulate coated acid is believed to promote a more simultaneous release of the components of the composition than is achieved by prior art acid-protection techniques, thus enhancing, and making more consistent, the bioavailability of the active peptide compounds. | 2012-02-16 |
20120040001 | DISINTEGRATING PARTICLE COMPOSITION AND RAPIDLY DISINTEGRATING COMPRESSION-MOLDED MATERIAL USED THE SAME - [Subject Matter] | 2012-02-16 |
20120040002 | RESORBABLE AND BIOCOMPATIBLE FIBRE GLASS COMPOSITIONS AND THEIR USES - Biocompatible and resorbable melt derived glass compositions which include: SiO | 2012-02-16 |
20120040003 | ANTI-DANDRUFF COMPOSITIONS WITH CITRUS FIBERS - A shampoo composition is described which includes from 1 to 25% by weight of mild surfactants, from 0.001 to 5% by weight of citrus fibers, from 0.01 to 5% by weight of anti-dandruff zinc salts, and a cosmetically acceptable carrier. The citrus fibers help structure the composition to maintain phase stability, provide appropriate viscosity and achieve deposition of the anti-dandruff zinc salts. | 2012-02-16 |
20120040004 | TREATMENT OF RADIATION-INDUCED FIBROSIS - The present invention relates to treatment or prevention of radiation induced fibrosis using TNF-alpha antagonism. Preferably, TNF-alpha is antagonized by direct binding or by inhibition of synthesis. In a preferred embodiment, the invention comprises intraperitoneal administration of a chitosan-siRNA nanoparticle, wherein the siRNA is targeted to the mRNA encoding TNF-alpha. | 2012-02-16 |
20120040005 | NANOSTRUCTURED CALCIUM-SILVER PHOSPHATE COMPOSITE POWDERS, PROCESS FOR OBTAINING THE POWDERS, AND BACTERICIDAL AND FUNGICIDAL APPLICATIONS THEREOF - Described in example embodiments are nanocomposite powders including calcium phosphate and silver nanoparticles on the surface of the calcium phosphate. Other example embodiments, describe methods of forming nanocomposite powders comprising a) preparing a nanometric calcium phosphate by a sol-gel processing route; and b) depositing silver nanoparticles on the calcium phosphate surface. Compositions including nanocomposite powders and uses of those compositions are also described. | 2012-02-16 |
20120040006 | Pharmaceutical Compositions Comprising Brivaracetam - The present invention relates to a pharmaceutical composition comprising brivaracetam as active ingredient, the invention relates specifically to a prolonged release formulation. | 2012-02-16 |
20120040007 | SERINE PALMITOYLTRANSFERASE INHIBITORS FOR PREVENTING AND DELAYING RETINITIS PIGMENTOSA - The method for preventing and delaying inherited retinal degenerations using serine palmitoyltransferase inhibitors, and compositions which contain them. | 2012-02-16 |
20120040008 | PHARMACEUTICAL COMPOSITIONS OF METABOTROPIC GLUTAMATE 5 RECEPTOR (MGLU5) ANTAGONISTS - Pharmaceutical compositions of metabotropic glutamate 5 receptor (mGlu5) antagonists or a pharmacologically acceptable salt thereof are disclosed. The compositions contain the therapeutic active compound with non-ionic polymer and ionic polymer, binder and fillers in either matrix pellet, matrix tablet or coated pellets. The compositions provide a pH-independent in vitro release profile with NMT 70% in one hour, NMT 85% in 4 hour, and NLT 80% in 8 hours. The compositions are useful for the treatment of CNS disorders, such as Treatment-Resistant Depression (TRD) and Fragile X Syndrome. | 2012-02-16 |
20120040010 | MICROPARTICULATED VACCINES FOR THE ORAL OR NASAL VACCINATION AND BOOSTERING OF ANIMALS INCLUDING FISH - The invention relates to a composition and a method for manufacturing semi-dry or dry particles containing a mucoadhesive polymer and a bioactive agent such as, but not limited to, an Immunogenic Substance (e.g., a vaccine), that allows the oral or nasal administration and delivery of the bioactive agent essentially unaltered to mucosal surfaces in the animal, including an aquatic animal. | 2012-02-16 |
20120040011 | ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS - 1,3-Dipole-functional compounds (e.g., azide functional compounds) can be reacted with certain alkynes in a cyclization reaction to form heterocyclic compounds. Useful alkynes (e.g., strained, cyclic alkynes) and methods of making such alkynes are also disclosed. The reaction of 1,3-dipole-functional compounds with alkynes can be used for a wide variety of applications including the immobilization of biomolecules on a substrate. | 2012-02-16 |
20120040012 | THERAPEUTIC STEM CELL NUTRIENT COMPOSITION AND USES THEREOF - The present invention relates to a composition and uses thereof for treatment of damaged tissue comprising at least one essential amino acid in L form and at least one essential lipid; wherein the composition is administered to a mammal suffering from severe tissue damage. The invention further relates to a composition and uses thereof comprising the mixture of one or more free L-amino acids in which the molar ratio of the free L-amino acids corresponds to the molar ratio of amino components in a mammalian tissue protein; and at least one essential lipid. | 2012-02-16 |
20120040013 | Regenerative Tissue Scaffolds - Methods, mixtures, and kits related to treating tissue are provided. The methods, mixtures, and kits can include an acellular tissue matrix, a polymer, and a solvent and may be capable of producing tissue scaffolds. The tissue scaffolds may be able to form a stable, three-dimensional shape in situ and elicit a limited immunologic or inflammatory response. | 2012-02-16 |
20120040014 | LIPID Supplements for Maintaining Health and Treatment of Acute and Chronic Disorders - Nutritional supplement formulations suitable for specific enhancement of cell and mitochondrial function comprise enriched formulations of phospholipids and chemical precursors containing specifically identified concentrations of phosphatidylglycerol, phosphatidic acid and phosphatidylcholine, and mitochondrial and cell membrane phospholipid molecules as well as other desirable constituents. Methods of enriching extracted sources of cell and mitochondrial membrane molecules and precursors from microbes, plants and other sources are also set forth. The formulae can be combined with nutritional, prebiotic, and probiotic (microbial) factors that increase bioavailability through the digestive tract and increase absorption at the cellular and subcellular levels. These lipid combinations can be used to treat mitochondrial disorders associated with medical pathologies, chronic illnesses and syndromes, or to maintain lipid balance for normal mitochondrial function, and can be administered in many different forms. The various combinations specifically enriched in the correct phospholipid and correct fatty acid residues can be used to treat organ, tissue, cell or system. | 2012-02-16 |
20120040015 | BIOCOMPATIBLE COMPOSITE AND ITS USE - A composite material including biocompatible and bioresorbable glass, a biocompatible and bioresorbable matrix polymer and a coupling agent capable of forming covalent bonds. The composite also includes a compatibilizer, where at least 10% of the structural units of the compatibilizer are identical to the structural units of the matrix polymer, and the molecular weight of the compatibilizer is less than 30000 g/mol. The use of this composite, a medical device which includes the composite and a method for preparing the composite are also disclosed. | 2012-02-16 |